Akums Records Impressive Growth Amid Global Expansion

Akums Drugs & Pharmaceuticals Ltd., India's largest CDMO, has reported impressive financial growth for the fiscal year ending March 31, 2026. The company's robust performance was fueled by the core domestic CDMO business, international market expansions, and regulatory achievements despite challenges in the API segment. Significant milestones include European regulatory approvals and new global ventures.

Akums Drugs & Pharmaceuticals Ltd., India's leading Contract Development and Manufacturing Organisation (CDMO), announced commendable financial results for Q4 and the full fiscal year ending March 31, 2026. The company's revenue surged by 9.7% year-over-year in the fourth quarter, tallying up to Rs. 1,158 crore.

Key growth drivers included robust domestic CDMO operations and international expansion initiatives, such as achieving regulatory milestones and tapping into European markets. Adj EBITDA witnessed a substantial 61.6% rise compared to the same quarter last year, underscoring effective operational strategies.

Despite challenges in the API sector, Akums has maintained a focus on portfolio optimization and cost control. The company also launched several automation initiatives aimed at achieving long-term progress and sustainability in the global pharmaceutical industry.